<DOC>
	<DOCNO>NCT00285389</DOCNO>
	<brief_summary>Phase II study test first line VAD ( Vincristine Adriablastine Dexamethasone ) + C ( Chlorambucil ) regimen associate rituximab ( R-VAD + C ) cohort young patient 66 year mantle cell lymphoma also test role vivo marrow purge rituximab autologous stem cell transplantation consolidation patient fulfil response 4 cycle ( R VAD + C ) regimen .</brief_summary>
	<brief_title>Treatment Mantle Cell Lymphoma Diagnosis Patients Under 65 Years</brief_title>
	<detailed_description>All patient diagnosis stage II , III IV arbor disease treat 4 cycle ( R VAD +C ) . The responder RP &gt; 50 % receive 2 cycle intensify alkeran 140 mg/ m2 8 gray TBI 4 day autologous PBSCT.The stem cell collection realise mobilisation HD Cyclophosphamide ( 4 mg/m2 ) four R- ( VAD + C ) cycle purge rituximab injection 10 day collection . There clinical molecular evaluation strategy</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Mantel cell lymphoma CD 20+ At diagnosis without anterior chemotherapy Age &gt; 18 &lt; 66 year Ann Arbor ii , III IV ECOG &lt; 3 contraindication rituximab treatment Informed consent sign No cancer anteriory Renal hepatic function compatible treatment Ventricular Fraction &gt; 50 % echographic method &gt; 40 % isotopic method Other type lymphoma age &lt; 18 ou &gt; 66 year Informed consent sign anterior cancer Contraindication rituximab Cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Autologous PBSCT</keyword>
	<keyword>Molecular evaluation</keyword>
</DOC>